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1. Introduction 
The worldwide incidence of malignant melanoma is increasing at an alarming rate. The 
importance of diagnosing nodal metastatic disease has impacted significantly on the 
accurate staging and stratification of melanoma patients. As a minimally invasive procedure 
with low morbidity, sentinel lymph node mapping allows for a detailed histopathologic 
evaluation involving multiple sections, H&E staining in combination with 
immunohistochemical staining of the node with the highest chance of containing metastatic 
foci. Controversy exists regarding the appropriate selection of patients for sentinel lymph 
node biopsy, particularly among patients with thin melanomas (< 1 mm Breslow thickness), 
thick melanomas (> 4 mm Breslow thickness), locally recurrent melanoma, nodular 
melanomas and those affecting the head and neck region. Furthermore, debate continues 
with regard to false-negative rates, managing in-transit disease, therapeutic benefit and 
alternatives, such as ultrasound guided biopsy. 
In malignant melanoma, no standard systemic adjuvant therapy with confirmed impact on 
overall survival has been identified thus far for clinically node negative stage I-II patients 
after excision of the primary, or for clinically node positive stage III patients after lymph 
node dissection for metastatic regional node involvement. Thus some argue about the initial 
merits of performing the sentinel node procedure at all. 
The aims of this book chapter are  
1. to examine the impact of sentinel node biopsy on outcome in melanoma,  
2. determine the effect, if any, of stage migration in melanoma   
3. to clarify the impact of the different clinical sites on outcome, 
4. to ascertain the reasons behind a lack of universal adoption of sentinel node biopsy in 
melanoma and  
5. to critically assess other emerging strategies in the management of melanoma including 
frozen section analysis of the sentinel node, imprint cytology of the sentinel node, 
targeted assessment of the regional lymph node basin, the use of risk stratification 
algorithms of histological factors of the primary tumour and microRNAs. 
2. Impact of sentinel node biopsy on outcome in melanoma 
The key to survival for patients with melanoma is early detection and treatment of 
metastatic disease as this may improve disease-free and overall survival rates (Pacifico, 
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Grover, and Sanders 2004). The status of the regional lymph node basin has been widely 
shown to be the most important prognostic indicator for patients diagnosed with cutaneous 
melanoma (Balch et al. 2001). The disease-free survival and overall survival is dependent on 
the initial disease burden, thus melanomas less than 1mm rarely metastasise while at least 
25% of melanomas between 1.5 and 4.0mm and greater than 60% of melanomas greater than 
4.0mm thick will have lymph node metastases at presentation (Balch et al. 2001). The disease 
also depends heavily on the stage at presentation. Patients with early stage disease (i.e. < 
1mm thick) achieve long-term survival in more than 90% of cases. However, patients with 
melanomas greater than 1.0mm thickness have survival rates ranging from 50%-90% (Balch 
et al. 2001).  
The introduction of the sentinel lymph node biopsy (SLNB) technique for the evaluation of 
patients with truncal and extremity melanoma by Morton et al in 1992 showed that the status 
of the SLN accurately represented the status of the entire nodal basin from which it was 
obtained. This study highlighted a novel technique of identifying patients with occult nodal 
metastasis who warranted possible further therapeutic lymphadenectomy and adjuvant 
therapy, whilst also sparing the remaining 80% of patients without regional disease the 
morbidity associated with a formal lymphadenectomy procedure (Morton et al. 1992).  
The benefits to performing SLNB versus elective lymphadenectomy are well supported 
(Pawlik, Ross, and Gershenwald 2004). SLNB is associated with less morbidity and is cheaper 
to perform (Wrightson et al. 2003). Historically two studies showed a survival benefit in 
patients who had SLNB performed (Dessureault et al. 2001; Kretschmer et al. 2004). 
Furthermore a positive sentinel node, Breslow thickness, age and male gender were all 
independent predictors of overall survival on multivariate analysis (Kretschmer et al. 2004). 
The proven benefits for performing SLNB at the time of oncological wide local excision of a 
primary melanoma in any patient, include both prognostic and staging information, the 
potential therapeutic impact of a completion lymph node dissection in those with a positive 
SLN and also has implications of SLN status for adjuvant therapy decisions or entry into 
pertinent clinical trials. Because the status of the regional lymph nodes is the most single 
important prognostic factor for patients with melanoma, obtaining this information is 
essential (Shaw et al. 1985).  
The preliminary findings of the MSLT-1 trial (Multicentre Selective Lymphadenectomy 
Trial) represent the first randomised prospective clinical study to show a potential survival 
advantage to performing sentinel lymph node biopsy in patients with melanoma (Morton et 
al. 2006). The study included 1269 patients with intermediate thickness (1.2-3.5mm) primary 
melanomas randomised to either a wide local excision and observation of regional lymph 
nodes with lymph node dissection if nodal relapse occurred (n=500) or to a wide local 
excision and SLNB with immediate regional lymphadenectomy if nodal micrometastases 
were found (n=769).  
There was no difference in overall 5-year melanoma-specific survival rate; 87.1% for the 
SLNB and 86.6% in the control arm. However, the study did show improved disease-free 
survival in those patients who underwent the SLNB compared to those in the nodal 
observation arm group; the 5-year survival rate for node positive melanoma was 72.3 ± 4.6% 
and 90.2 ± 1.3% in the node negative group (hazard ratio for death, 2.48; 95% confidence 
interval, 1.54 to 3.98; P < 0.001).  
The incidence of sentinel-node micrometastases was 16.0% and the rate of nodal relapse in 
the observation group was 15.6%. The corresponding mean number of tumour-involved 
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nodes was 1.4 in the biopsy group and 3.3 in the observation group (P<0.001), indicating 
disease progression during observation. Among patients with nodal metastases, the 5-year 
survival rate was higher among those who underwent immediate lymphadenectomy than 
among those in whom lymphadenectomy was delayed (72.3+/-4.6% vs. 52.4+/-5.9%; hazard 
ratio for death, 0.51; 95% confidence interval, 0.32 to 0.81; P=0.004) (Morton et al. 2006). The 
study authors concluded that the staging of intermediate-thickness (1.2 to 3.5 mm) primary 
melanomas according to the results of SLNB provided important prognostic information. 
However, the study did not show a clear survival advantage associated with SLNB.  
Further subset analysis from MSLT-1 comparing patients with a positive SLNB + immediate 
lymphadenectomy versus those in the nodal observation group showed that there was 
significant progression to more advanced nodal disease in the nodal observation group and 
more importantly that there was a significant survival advantage in those undergoing 
immediate lymphadenectomy. 
In order to appreciate the full potential applicability of the results from MSLT-1, it is 
important to consider the results from the WHO Truncal Melanoma international 
multicentre randomised trial which examined the use of early elective lymph node 
dissection (ELND) at the time of WLE of truncal melanomas > 1.5mm versus delayed 
lymphadenectomy until appearance of regional-node metastases (Balch et al. 2000). Firstly, 
this trial in addition to one carried out in Europe and published 2 years before (Cascinelli et 
al. 1998) under the title of WHO Melanoma Programme, did show a trend for improved 
survival in those patients who had ELND at the time of WLE, however this was not 
significant. But they did show improved 5-year survival rates in patients with occult 
regional node metastases 48% versus 27% in patients in whom the regional node dissection 
was delayed until the time of appearance of regional node metastases, which indeed was 
significant. The patients with regional nodes that became clinically and histologically 
positive during follow-up had the poorest prognosis. They concluded that SLNB may 
become a tool to identify patients with occult node metastases, who could then undergo 
node dissection (Balch et al. 2000). 
These same authors showed that nodal micrometastatic deposits detected by the SLNB will 
become clinically relevant disease eventually therefore the logic of removing these involved 
lymph node deposits early may improve patient prognosis (Morton, Cochran, and 
Thompson 2007). Numerous reasons are cited in an article by Ross et al detailing exactly 
why the microscopic metastases in sentinel lymph nodes would most likely progress to 
palpable disease if left intact (Ross and Gershenwald 2008).  
Most recently, an international panel comprising a cross section of expert melanoma surgeons 
who have contributed data and leadership to further investigate the role of SLNB in melanoma 
recently produced a consensus statement, outlining their overall interpretation of current 
evidence, as a guide to clinical treatment of patients with clinically localized melanoma. They 
agreed that SLNB is standard of care in current practice because it is incorporated in staging 
guidelines from the AJCC, incorporated in the treatment guidelines from the National 
Comprehensive Cancer Network, and practiced by most specialty surgeons who treat 
melanoma in the United States, Australia and Western Europe (Balch et al. 2009).  
3. Stage migration effect 
Oncologically, the prognosis for malignant disease is largely determined by the metastatic 
potential of the primary tumour. Some authors argue that we cannot alter prognosis by 
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early detection and surgical intervention of involved regional nodes, highlighting the 
balance between nihilistic pre-determinism and active management. As an oncological 
community, we have a greater understanding of the mechanisms of action for 
haematological spread versus lymphatic spread. For many malignancies we know that 
regional lymphadenectomy improves survival. As to just how far this lymph node 
dissection is directly therapeutic remains a persistent source of controversy in melanoma.  
Many believe that stage-adjusted survival benefit is due in part to the phenomenon of stage 
migration (Will Rodgers phenomenon). In medical stage migration, improved detection of 
illness (eg when newer technology allows for more sensitive detection of tumour spread) 
leads to the movement of people from the set of healthy people to the set of unhealthy 
people. Because these people are not healthy, removing them from the set of healthy people 
increases the average lifespan of the healthy group. Likewise, the migrated people are 
healthier than the people already in the unhealthy set, so adding them raises the average 
lifespan of that group as well. Both lifespan are statistically lengthened, even if early 
detection of a cancer does not lead to better treatment - because it is detected earlier, more 
time is lived in the "unhealthy" set of people. It was originally described in 1985 (Feinstein, 
Sosin, and Wells 1985). Rodgers’ original quote -“When the Okies left Oklahoma and moved 
to California, they raised the average intelligence level in both states” - illustrates the theme. 
It has been shown that stage migration is responsible at least in part for an apparent 
improvement in survival for patients with stage III and IV non–small cell lung cancer in the 
era of PET scanning (Chee et al. 2008). It has also been demonstrated in urological, prostate 
and laryngeal malignancies (Albertsen et al. 2005; Champion and Piccirillo 2004; Gofrit et al. 
2008). A large population-based study assessing the surgical treatment trends for 18449 
patients with melanoma in the era of sentinel node biopsy using a SEER database concluded 
that stage migration is evident with increasing use of SLN biopsy (Cormier et al. 2005). 
Furthermore, the theme underlying this phenomenon may no longer be confined to 
interpreting oncology trials as its’ use has been cited in other paramedical arenas including 
healthcare economics. Young et al studied the measured differences in health care utilisation 
across an indemnity and managed care plan, finding that apparent increases in utilisation in 
both plans disappeared when viewed together, reflecting the migration of sicker patients 
from indemnity to managed care plans (Young et al. 1999).  
4. Impact of histological site on outcome 
While SLNB has a defined role in cutaneous melanomas of the trunk and extremities, 
several questions remain unanswered with respect to its application in the head and neck 
region. These account for up 21% of all melanomas diagnosed annually (Gillgren et al. 2000; 
Golger et al. 2007; Lachiewicz et al. 2008), have worse outcomes relative to melanomas of the 
trunk and extremities (Gillgren et al. 2000; Lachiewicz et al. 2008), clinically manifest as 
thicker lesions at their initial diagnosis and thus present at an advanced stage (Gillgren et al. 
2000; Hoersch, Leiter, and Garbe 2006). SLNB for melanomas of the head and neck regions is 
limited by technical difficulties with specific concern surrounding damage to vital structures 
such as the facial nerve (Eicher et al. 2002). There is growing concern surrounding the 
reliability of the SLN to accurately predict the disease status of the entire nodal basin. In the 
head and neck region, the complexity and variability of the interlacing network of cervical 
lymphatics was highlight by O’Brien et al who showed a 34% discordance rate between the 
clinical prediction of lymphatic drainage and lymphoscintigraphy findings in 97 cases of 
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cutaneous melanoma of the head and neck (O'Brien et al. 1995). A recent study from the 
John Wayne Cancer Institute reported a 'false negative' rate of 8.9%, identifying increasing 
tumour thickness, the presence of ulceration and head/neck primary tumours as risk factors 
for the development of recurrence in the presence of a negative node (Gershenwald et al. 
1998). A recent study from the Sydney Melanoma Unit showed that up to 30% of patients 
with lymph node metastases from neck melanomas bypass the nearest node and involve 
nodes at more distant sites (Pathak et al. 2001), so called “skip metastases”. 
Numerous studies have evaluated the survival differences between head and neck 
melanoma versus those of the trunk and extremities and have found that those with 
melanoma of the head and neck have relatively poorer outcome (Gillgren et al. 2000; 
Lachiewicz et al. 2008; Thorn et al. 1989).  
Specifically in a study involving 51,704 patients with melanoma, 5- and 10-year Kaplan-
Meier survival probabilities for scalp/neck melanoma were 83.1% and 76.2%, respectively, 
compared with 92.1% and 88.7%, respectively, for melanoma of the other sites, including 
extremities, trunk, face, and ears. They found that patients with melanoma of the scalp/neck 
had an 84% greater chance of melanoma-related death compared with those with 
melanomas of the extremity (Lachiewicz et al. 2008). Within this head and neck group, 
another large population-based study involving 27,097 patients to evaluate tumour location 
as a prognostic factor in patients with head and neck melanoma (using the Surveillance, 
Epidemiology, and End Results (SEER) database), showed a 10-year overall survival rate of 
56% and a disease free survival rate of 85%, respectively with those patients diagnosed with 
scalp/neck melanoma having poorer survival versus those with facial melanoma (Tseng 
and Martinez). 
5. Lack of universal adaptation of sentinel node procedure 
There has been some international criticism leveled directly at the manner in which MSLT-1 
was carried out and the conclusions derived from it (Thomas 2006, 2009). Stated evidence 
that, tiny sentinel nodal deposits of melanoma have no prognostic relevance and will not 
progress or disseminate further as determined by the hosts’ immune system, is now 
accruing. Associating a poorer prognosis to these deposits is called prognostic false 
positivity; which can lead to patients being incorrectly upstaged, undergoing unnecessary 
completion lymphadenectomy and possibly unnecessary adjuvant therapy (Thomas 2008). 
The results of the fourth interim analysis of MSLT-I support the hypothesis that prognostic 
false-positivity is the explanation for the large survival advantage claimed for patients 
having early lymphadenectomy versus delayed lymphadenectomy. Further detailed 
analysis of the results of MSLT-1 suggested that the incidence of prognostic false positivity 
is about 24% in patients with intermediate thickness melanoma and 34% for all patients 
(Thomas 2008). Further credence is given to this stance from studies confirming that patients 
with these tiny deposits of nodal melanoma (ie detected by immunohistochemistry alone or 
<0.1mm in size), have similar prognosis to those who are sentinel node negative 
(Spanknebel et al. 2005; van Akkooi et al. 2006). 
Some believe that a positive sentinel node is likely to be associated with disseminated 
melanoma deposits elsewhere because they believe that melanoma tumour biology is not 
predictable. Are these cells released into the circulation, either lymphatic or blood vascular, 
disseminating widely and beyond? The timing of their manifestation is that which is 
unpredictable. These disseminated deposits (nodal, in-transit or distant disease) may 
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become clinically apparent at some point in time, in spite of a positive sentinel node (and 
subsequent regional lymphadenectomy). Thus, assessment histologically of the sentinel 
node and the extent or number of lymph node deposits does not confer any additional 
benefit to patients, apart from the fact that they have melanoma deposits outside of their 
primary site and that in time they are at greater risk of further distant disease. 
Some experts argue against the routine use of SLNB as they feel that it is associated with an 
increased risk of in-transit disease, however this has been readily refuted by evidenced 
based study who showed that there was no significant difference in the rate of in-transit 
metastasis between patients who had WLE alone (4.9%) and those who had WLE + SLNB 
(4.5%) (Pawlik et al. 2005).   
Clinicians opposed to the use of the sentinel node will argue that in spite of its’ prognostic 
importance, there is still no clear evidence to support a direct survival advantage from the 
procedure alone and, that no effective adjuvant therapy (including vaccines, combinations 
of chemotherapeutic agents, immunostimulants, cytokines and growth factors) has been 
heretofore discovered and subsequently proven to be of clear benefit (unequivocally 
prolongs overall survival) in clinical trials to date for these patients (Otley and Zitelli 2000; 
Thomas and Patocskai 2000; Eggermont and Gore 2007; Sabel and Sondak 2002; Spitler 
2002).  
Confusion remains whether early completion lymphadenectomy imparts a survival 
advantage when compared directly to those patients who wait until clinically occult nodal 
metastatic disease becomes apparent. Some authors site compelling evidence that the 
assessment of the sentinel node in melanoma is of no benefit whatsoever, does not alter the 
course of melanoma that has metastasised and should be immediately abandoned from 
current practice (Medalie and Ackerman 2004). There is growing concern surrounding the 
reliability of the SLN to accurately predict the disease status of the entire nodal basin. 
Specific problems have been identified in the head and neck region where the complexity 
and variability of the interlacing network of cervical lymphatics was highlighted by O’Brien 
et al who showed a 34% discordance rate between the clinical prediction of lymphatic 
drainage and lymphoscintigraphy findings in 97 cases of cutaneous melanoma of the head 
and neck (O'Brien et al. 1995).  
Regional nodal failures in melanoma patients following a negative SLNB are not common. 
Various reasons have been suggested as to why SLNM fails which include (1) when the 
primary lesion is overlying the draining lymph node basin, (2) learning curve of the 
performing surgeon / pathologist / nuclear medicine staff, (3) inappropriately high 
radioactivity level, (4) movement of the dye into the second or non-sentinel lymph node and 
(5) incorrect injection technique of the dye. It has been suggested that at least a 30 person 
learning curve be recommended for a surgeon performing these cases (Morton et al. 1999). 
Patients undergoing SLNM for cutaneous melanoma should be managed via a multi-
disciplinary team and the overall success rate of the procedure may be attributable in some 
part to this. 
It is also well recognised that 11–12% (Gadd et al. 1999; Gershenwald et al. 1998) of patients 
whose sentinel node apparently doesn’t harbour cells of melanoma subsequently develop 
signs of metastatic melanoma disease and conversely patients whose sentinel node does 
harbour metastatic cells may succumb to their illness in months or they may survive for 
decades. This high figure does little to add confidence to the therapeutic benefit of sentinel 
node biopsy. 
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6. Other emerging strategies  
In an ideal oncological world, intra-operative evaluation of the sentinel node for metastatic 
disease allows a simultaneous completion lymphadenectomy if a positive deposit is 
immediately identified, preventing the higher costs and additional morbidity associated 
with a second operation. There is evidence that the sentinel node biopsy procedure is cost-
effective compared to wide excision alone (Morton, Howard, and Thompson 2009). Here we 
discuss some of the emerging strategies addressing this specific issue.  
Frozen section analysis of the lymph node was studied in 368 patients with primary 
cutaneous melanoma ≥1mm or Clarks level IV. 20% (74/368) of sentinel nodes were 
identified by traditional H&E and immunohistochemical stains, and further frozen sectioning 
only identified the metastases in 59% (44/74) of these patients (Stojadinovic et al. 2002). The 
SLN was the only positive lymph node in 86% (64/74) of patients. Additional positive non-
SLNs were identified in 10 of 74 patients (14%). This low sensitivity was confirmed in other 
subsequent studies (Koopal et al. 2000; Tanis et al. 2001). The authors do suggest the potential 
use of frozen sectioning of a sentinel node found within the parotid gland or neck, thereby 
reducing the risk of facial and spinal accessory nerve injury during a second operative 
procedure. Frozen sectioning is a technically difficult procedure to perform and results in 
freezing artefact of the lymph node, rendering it unsuitable for further analysis. 
Another recent development concerning the sentinel node is imprint cytology, which 
involves bisecting the node, imprinting it and subsequently staining the relevant sections. 
One study involving 93 patients showed that imprint cytology had a sensitivity and 
specificity of 38% and 100% respectively (similar figure to that of frozen section) (Creager et 
al. 2002). Even though it is easier to perform this procedure and without subsequent damage 
to the lymph node, the low sensitivity severely limits its use in the routine evaluation of the 
sentinel node. Other algorithms of histological factors concerning the primary tumour have 
also been developed (vertical growth phase, tumour infiltrating lymphocytes, mitotic rate 
and thickness) (Kruper et al. 2006). These are able to stratify patients into high and minimal 
risk for sentinel node disease based on the analysis of their primary lesion, and upon 
validation, these models could possibly provide a clinically useful tool for making treatment 
decisions (remove the use of the sentinel node procedure in those with minimal risk), aid in 
assessing patient risk, and for planning and analyzing clinical trials (Soong et al.).  
Some molecular biology techniques for the staging of regional lymph nodes have yielded 
promising results (Wang et al. 1994). Wang et al, using real-time PCR to identify tyrosine 
messenger RNA for the detection of micrometastatic lymph node disease, showed that this 
was a highly sensitive and clinically applicable method to detect micrometastases (tyrosine 
messenger RNA is found almost exclusively in melanocytes). Furthermore, studies using 
reverse transcription and polymerase chain reaction to determine tyrosinase mRNA in 
peripheral blood, (which indicates the presence of circulating melanoma cells), showed that 
this may be a promising serum marker for melanoma staging and for predicting recurrence, 
prognosis and response to immune therapy (Brossart et al. 1993). The same group found 
that the amount of circulating tumour cells correlates with the tumour burden and that in 
patients with regression of melanoma metastases after immunotherapy, a decrease of the 
amount of tumour cells in the peripheral blood was observed (Brossart et al. 1995), 
associating the rate of positivity with stage of the disease. 
There is accumulating evidence to support the use of targeted ultrasound assessment of the 
regional nodal basin at the time of diagnosis of the primary tumour, thus enhancing routine 
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clinical palpation. It is possible to identify deposits as small as 3-4mm (Bafounta et al. 2004). 
This does not take into account those nodal deposits below that diameter ie <3mm. Voit et al 
showed that specific features on preoperative ultrasound (peripheral perfusion, balloon 
shape and loss of central echoes) and fine needle aspiration cytology can identify 65% of 
sentinel node metastases and thus reduce the need for surgical procedures on the sentinel 
node, allowing those patients identified to proceed directly to completion 
lymphadenectomy (Voit et al.). However these results must be considered with caution. 
Ultrasound is heavily user-dependent. Given the fact that some patients will present with 
micrometastatic deposits in their regional nodes that will not be identifiable on ultrasound 
lowers its’ sensitivity. Therefore, a negative ultrasound is not a reliable substitution for 
biopsy and subsequent histopathological examination of the sentinel node. 
MicroRNAs (miRNAs) are non-coding short ribonucleic acid molecules that are post-
transcriptional regulators that bind to complementary sequences in the three prime 
untranslated regions of mRNAs, leading to gene silencing. MiRNAs are present in human 
plasma in a very stable form that is protected from endogenous RNase activity (Mitchell et 
al. 2008). There has been a recent surge in reports demonstrating the use of miRNAs as 
modulators of gene expression and their potential role as both diagnostic and prognostic 
markers in many malignancies (Iorio and Croce 2009; Osaki, Takeshita, and Ochiya 2008). 
This is also true for malignant melanoma, where it has been shown that serum levels of miR-
221 were significantly increased in melanoma patients, differentiated between in situ and 
invasive disease, were useful in evaluating tumour progression and monitoring patients 
during follow-up and that levels of of miR-221 correlated with tumour thickness (Kanemaru 
et al.). 
7. Conclusion 
In spite of a lack of definitive evidence associating a positive SLNB result and increased 
survival rate, the routine use of this novel approach is justified in patients presenting with 
primary cutaneous malignant melanoma because it provides valid and reliable staging 
information about the regional nodes using a minimally invasive technique, allows for 
regional disease control in the presence of a positive sentinel node and increases the 
potential for cure in patients with at least intermediate thickness disease. Cumulative 
evidence from MSLT-1, ELND trials and large retrospective trials mentioned above support 
the view that survival is better for patients with clinically occult sentinel node deposits. 
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